ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13
locus and/or mutation (s) within the TP53 gene, are associated with resistance to …
locus and/or mutation (s) within the TP53 gene, are associated with resistance to …
Precision diagnostics in chronic lymphocytic leukemia: Past, present and future
J Mollstedt, L Mansouri, R Rosenquist - Frontiers in Oncology, 2023 - frontiersin.org
Genetic diagnostics of hematological malignancies has evolved dramatically over the years,
from chromosomal banding analysis to next-generation sequencing, with a corresponding …
from chromosomal banding analysis to next-generation sequencing, with a corresponding …
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Background Chronic lymphocytic leukemia (CLL) primarily affects older persons who often
have coexisting conditions in addition to disease-related immunosuppression and …
have coexisting conditions in addition to disease-related immunosuppression and …
Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
D Rossi, H Khiabanian, V Spina… - Blood, The Journal …, 2014 - ashpublications.org
TP53 mutations are strong predictors of poor survival and refractoriness in chronic
lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical …
lymphocytic leukemia (CLL) and have direct implications for disease management. Clinical …
Drug-perturbation-based stratification of blood cancer
As new generations of targeted therapies emerge and tumor genome sequencing discovers
increasingly comprehensive mutation repertoires, the functional relationships of mutations to …
increasingly comprehensive mutation repertoires, the functional relationships of mutations to …
p53-dependent non-coding RNA networks in chronic lymphocytic leukemia
Mutations of the tumor suppressor p53 lead to chemotherapy resistance and a dismal
prognosis in chronic lymphocytic leukemia (CLL). Whereas p53 targets are used to identify …
prognosis in chronic lymphocytic leukemia (CLL). Whereas p53 targets are used to identify …
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
J Malcikova, K Stano-Kozubik, B Tichy, B Kantorová… - Leukemia, 2015 - nature.com
In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects
with the affected patients being potentially directed to alternative treatment. Therapy …
with the affected patients being potentially directed to alternative treatment. Therapy …
Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
Genome studies of chronic lymphocytic leukemia (CLL) have revealed the remarkable
subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are …
subclonal heterogeneity of the tumors, but the clinical implications of this phenomenon are …
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL
R Guièze, P Robbe, R Clifford… - Blood, The Journal …, 2015 - ashpublications.org
Abstract Although TP53, NOTCH1, and SF3B1 mutations may impair prognosis of patients
with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these …
with chronic lymphocytic leukemia (CLL) receiving frontline therapy, the impact of these …
The impact of SF3B1 mutations in CLL on the DNA-damage response
GD te Raa, IAM Derks, V Navrkalová, A Skowronska… - Leukemia, 2015 - nature.com
Mutations or deletions in TP53 or ATM are well-known determinants of poor prognosis in
chronic lymphocytic leukemia (CLL), but only account for approximately 40% of chemo …
chronic lymphocytic leukemia (CLL), but only account for approximately 40% of chemo …